SI3654989T1 - Uporaba kladribina za zdravljenje avtoimunske nevromuskularne bolezni - Google Patents

Uporaba kladribina za zdravljenje avtoimunske nevromuskularne bolezni

Info

Publication number
SI3654989T1
SI3654989T1 SI201831074T SI201831074T SI3654989T1 SI 3654989 T1 SI3654989 T1 SI 3654989T1 SI 201831074 T SI201831074 T SI 201831074T SI 201831074 T SI201831074 T SI 201831074T SI 3654989 T1 SI3654989 T1 SI 3654989T1
Authority
SI
Slovenia
Prior art keywords
cladribine
treatment
neuromuscular disease
autoimmune neuromuscular
autoimmune
Prior art date
Application number
SI201831074T
Other languages
English (en)
Slovenian (sl)
Inventor
Konrad Rejdak
Original Assignee
Chord Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chord Therapeutics Sa filed Critical Chord Therapeutics Sa
Publication of SI3654989T1 publication Critical patent/SI3654989T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
SI201831074T 2017-07-21 2018-06-28 Uporaba kladribina za zdravljenje avtoimunske nevromuskularne bolezni SI3654989T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease
PCT/GB2018/051801 WO2019016505A1 (en) 2017-07-21 2018-06-28 USE OF CLADRIBINE FOR THE TREATMENT OF AUTOIMMUNE NEUROMUSCULAR DISEASE
EP18739593.4A EP3654989B1 (en) 2017-07-21 2018-06-28 Use of cladribine for treating autoimmune neuromuscular disease

Publications (1)

Publication Number Publication Date
SI3654989T1 true SI3654989T1 (sl) 2024-06-28

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201831074T SI3654989T1 (sl) 2017-07-21 2018-06-28 Uporaba kladribina za zdravljenje avtoimunske nevromuskularne bolezni

Country Status (16)

Country Link
US (2) US12171775B2 (OSRAM)
EP (2) EP3654989B1 (OSRAM)
JP (1) JP7186214B2 (OSRAM)
CA (1) CA3095893A1 (OSRAM)
DK (1) DK3654989T3 (OSRAM)
ES (1) ES2974423T3 (OSRAM)
FI (1) FI3654989T3 (OSRAM)
GB (1) GB2564717A (OSRAM)
HR (1) HRP20240282T1 (OSRAM)
HU (1) HUE066238T2 (OSRAM)
LT (1) LT3654989T (OSRAM)
PL (1) PL3654989T3 (OSRAM)
PT (1) PT3654989T (OSRAM)
RS (1) RS65246B1 (OSRAM)
SI (1) SI3654989T1 (OSRAM)
WO (1) WO2019016505A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) * 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
WO2025125527A1 (en) 2023-12-14 2025-06-19 Ares Trading S.A. Cladribine regimen for treating myasthenia gravis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
WO2001007054A1 (en) * 1999-07-22 2001-02-01 Supergen, Inc. Methods for treating autoimmune diseases
EP1556010A4 (en) * 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
EP1588283A2 (en) * 2002-11-22 2005-10-26 Transclick, Inc. System and method for language translation via remote devices
EA009714B1 (ru) 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
ES3007339T3 (en) 2004-12-22 2025-03-19 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EA020805B1 (ru) * 2006-05-24 2015-01-30 Мерк Сероно С.А. Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза

Also Published As

Publication number Publication date
DK3654989T3 (da) 2024-02-26
LT3654989T (lt) 2024-03-25
WO2019016505A1 (en) 2019-01-24
RS65246B1 (sr) 2024-03-29
GB2564717A (en) 2019-01-23
JP7186214B2 (ja) 2022-12-08
HRP20240282T1 (hr) 2024-05-10
US20250302858A1 (en) 2025-10-02
HUE066238T2 (hu) 2024-07-28
GB201711800D0 (en) 2017-09-06
EP4292663A2 (en) 2023-12-20
JP2020527156A (ja) 2020-09-03
PL3654989T3 (pl) 2024-05-20
EP3654989A1 (en) 2020-05-27
US12171775B2 (en) 2024-12-24
FI3654989T3 (fi) 2024-03-21
ES2974423T3 (es) 2024-06-27
EP4292663A3 (en) 2024-03-20
EP3654989B1 (en) 2024-01-03
US20200163986A1 (en) 2020-05-28
CA3095893A1 (en) 2019-01-24
PT3654989T (pt) 2024-02-28

Similar Documents

Publication Publication Date Title
IL269027A (en) Treatment of lag-3 positive tumors
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
IL256175A (en) Using exosomes to treat the disease
EP3370721A4 (en) TREATMENT OF OSTEOARTHRITIS
IL310483A (en) Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
EP3592428A4 (en) OPTOGENETIC INDUCTION OF NEURODEGENERATIVE PATHOLOGIES
EP3448263A4 (en) Electrotherapeutic treatment
EP3341074A4 (en) IMPLANTABLE STIMULATION ASSEMBLY
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
LT3463351T (lt) Parkinsono ligos gydymas
IL254173B (en) Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy
EP3614918C0 (en) CARDIAC ARRHYTHMIA TREATMENT SYSTEMS
EP3612133A4 (en) Implantable scaffolds for treatment of sinusitis
EP3458062A4 (en) Treatment of pain
EP3873528A4 (en) Rasopathy treatment
GB201401465D0 (en) Use of cladribine for treating autoimmune inflammatory disease
IL262801A (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
SI3654989T1 (sl) Uporaba kladribina za zdravljenje avtoimunske nevromuskularne bolezni
IL259381B (en) Mirabegron for the treatment of retinal diseases
EP3354284A4 (en) COMPOSITION FOR PAIN TREATMENT
GB201515244D0 (en) Treatment of inflammatory disease or condition
IL272422A (en) Methods for treating diseases of the meninges
SI3148588T1 (sl) N,N-bis-2-merkaptoetil izoftalamid za zdravljenje Parkinsonove bolezni